Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Papillary Carcinoma

Clinical Aspects

  • Chapter
Thyroid Cancer

Abstract

Papillary thyroid carcinoma (PTC) is a cancer of the thyroid follicular epithelium; like follicular carcinoma, it is the more highly differentiated of all of the classes of thyroid malignancy. The biological behavior of PTC varies widely, from small (<1.0 cm) tumors found at autopsy with surprisingly high frequency that show little evidence of invasion, to rapidly growing, locally invasive tumors that may be resistant to radioiodine therapy, eventually metastasizing and can cause death. To date, it has not been possible in a given patient to predict which course the tumor may take until several years, or even decades, of follow-up have elapsed. Fortunately, the overwhelming majority of tumors less than 1.5 cm in diameter tend to behave in a more biologically benign manner and can be completely cured with definitive therapy. This reflects the importance of tumor size on prognosis and risk of recurrence or death. Although PTC tends to affect women more often than men (ñ2:1), the risk of cancer in thyroid nodules in men is equally, if not more, significant because of the much lower frequency of any type of thyroid disease in men. This chapter deals with several clinical aspects of these tumors and descriptions of pathology and management appear in the immediate chapters that follow.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 339.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. Ca: a Cancer Journal for Clinicians 2005; 55:10–30.

    Google Scholar 

  2. Ain KB. Papillary thyroid carcinoma: etiology, assessment, and therapy. Endocr Metab Clin N Am 1995; 24:711–760.

    CAS  Google Scholar 

  3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297–306.

    Article  PubMed  CAS  Google Scholar 

  4. Chen AY, Levy L, Goepfert H, et al. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001; 92:225–231.

    Article  PubMed  CAS  Google Scholar 

  5. Robbins J, Merino MJ, Boice JD, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991; 115:133–147.

    PubMed  CAS  Google Scholar 

  6. Jain M, Khan A, Patwardhan N, et al. Follicular variant of papillary thyroid carcinoma: a comparative study of histopathologic features and cytology results in 141 patients. Endocr Pract 2001; 7:79–84.

    PubMed  CAS  Google Scholar 

  7. Kesmodel SB, Terhune KP, Canter RJ, et al. The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. Surgery 2003; 134:1005–1012.

    Article  PubMed  Google Scholar 

  8. Birmingham AR, Krishnan J, Davidson BJ, et al. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.

    Google Scholar 

  9. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Path 2004; 28:1336–1340.

    Article  PubMed  Google Scholar 

  10. van den Brekel MWM, Hekkenberg RJ, Asa SL, et al. Prognostic featues in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 1997; 107:254–259.

    Article  PubMed  Google Scholar 

  11. Prendiville S, Burman KD, Ringel MD, et al. Tall cell variant: An aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000; 122:352–357.

    Article  PubMed  CAS  Google Scholar 

  12. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 2004; 100:950–957.

    Article  PubMed  Google Scholar 

  13. Chao T-C, Lin J-D, Chen M-F. Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J Surg 2004; 28:393–396.

    Article  PubMed  Google Scholar 

  14. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19:545–576.

    PubMed  CAS  Google Scholar 

  15. Ito J, Noguchi S, Murakami T, et al. Factors affecting the prognosis of patients with carcinoma of the thyroid. Surg Gynecol Obstet 1980; 150:539.

    PubMed  CAS  Google Scholar 

  16. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:333–339.

    Article  PubMed  CAS  Google Scholar 

  17. AACE/AAES Medical/Surgical guidelines for clinical practice: management of thyroid carcinoma. Endocrine Practice 2001; 7:1–19.

    Google Scholar 

  18. Singer PA, Cooper DA, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well differentiated thyroid cancer. Arch Int Med 1996; 156:2165–2172.

    Article  CAS  Google Scholar 

  19. National Comprehensive Cancer Network (NCCN) Thyroid Carcinoma: Clinical Practice Guidelines 2005, J Natl Comprehensive Network 2005; 3:404–457.

    Google Scholar 

  20. British Thyroid Association. Guidelines for the management of differentiated thyroid cancer in adults. Available at: www.british-thyroidassociation.org/guidelines.htm, 2002.

    Google Scholar 

  21. Kashima K, Yokoyama S, Noguchi S, et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998; 8:197–202.

    PubMed  CAS  Google Scholar 

  22. Loh K-C, Greenspan FS, Dong F, et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:458–463.

    Article  PubMed  CAS  Google Scholar 

  23. Modi J, Patel A, Terrell R, et al. Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab 2003; 88:4418–4425.

    Article  PubMed  CAS  Google Scholar 

  24. Mechler C, Bounacer A, Suarez H, et al. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Brit J Cancer 2001; 85:1831–1837.

    Article  PubMed  CAS  Google Scholar 

  25. Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002; 26:897–902.

    Article  PubMed  Google Scholar 

  26. Alsanea O, Clark OH. Familial thyroid cancer. Current Opin Oncol 2001; 13:44–51.

    Article  CAS  Google Scholar 

  27. Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 86:5307–5312.

    Article  PubMed  CAS  Google Scholar 

  28. DeJong S, Demeter J, Jarosz H, et al. Primary papillary thyroid carcinoma presenting as cervical lymphadenopathy. Am Surg 1993; 59:172–177.

    CAS  Google Scholar 

  29. McConahey WM, Hay ID, Woolner LB, et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986; 61:978–996.

    PubMed  CAS  Google Scholar 

  30. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.

    Article  PubMed  CAS  Google Scholar 

  31. Falvo L, Catania A, D’Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg 2005; 241:640–646.

    Article  PubMed  Google Scholar 

  32. Miller JH, Marcus CS. Metastatic papillary thyroid carcinoma with normal thyroglobulin level. Clin Nutr Med 1988; 9:652.

    Article  Google Scholar 

  33. Robbins RJ, Srivastava S, Shaha A, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:6010–6016.

    Article  PubMed  CAS  Google Scholar 

  34. Kohlfuerst S, Igerc I, Lind P. Recombinant human thyrotropin is helpful in the follow-up and 131-I therapy of patients with thyroid cancer: A report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005; 15:371–376.

    Article  PubMed  CAS  Google Scholar 

  35. Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 2004; 14:959–963.

    Article  PubMed  Google Scholar 

  36. Wagner K, Arciaga R, Siperstein A, et al. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: Diagnostic synergy for detecting thyroid cancer. J Clin Endocrinol Metab 2005; 90:1921–1924.

    Article  PubMed  CAS  Google Scholar 

  37. Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 1997; 82:1638–1641.

    Article  PubMed  CAS  Google Scholar 

  38. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998; 83:4435–4442.

    Article  PubMed  CAS  Google Scholar 

  39. Thompson GB, Hay ID. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 2004; 28:1187–1198.

    Article  PubMed  Google Scholar 

  40. McClellan DR, Francis GL. Thyroid disease in children, pregnant women, and patients with Graves’ disease. Endocrin Metab Clin North Am 1996; 25:27–48.

    Article  CAS  Google Scholar 

  41. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 1988; 104:1157–1166.

    PubMed  CAS  Google Scholar 

  42. Mello CJ, Veronikis I, Fraire AE, et al. Metastatic papillary thyroid carcinoma to lung diagnosed by bronchoalveolar lavage. J Clin Endocrinol Metab 1996; 81:406–410.

    Article  PubMed  CAS  Google Scholar 

  43. Goldman ND, Coniglio JU, Falk SA. Thyroid cancers I: Papillary, follicular, and Hürthle cell. Otolaryngol Clin North Am 1996; 29:593–609.

    PubMed  CAS  Google Scholar 

  44. Cooper DS, Schneyer CR. Follicular and Hürthle cell carcinoma of the thyroid. Endocr Metab Clin North Am 1990; 19:577–592.

    CAS  Google Scholar 

  45. Grebe SKG, Hay ID. Follicular thyroid cancer. Endocr Metab Clin North Am 1995; 24:761–802.

    CAS  Google Scholar 

  46. Sisson JC, Jamadar DA, Kazerooni EA, et al. Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 1998; 8:215–221.

    PubMed  CAS  Google Scholar 

  47. Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Quart J Nucl Med 2004; 48:12–19.

    CAS  Google Scholar 

  48. Avram AM, Gielczyk R, Su L, et al. Choroidal and skin metastas from papillary thyroid cancer: Case and a review of the literature. J Clin Endocrinol Metab 2004; 89:5303–5307.

    Article  PubMed  CAS  Google Scholar 

  49. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endorinol Metab 2001; 86:1447–1461.

    Article  CAS  Google Scholar 

  50. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well differentiated thyroid cancer. Endocr Relat Cancer 2004; 11:97–116.

    Article  PubMed  CAS  Google Scholar 

  51. Kouvaraki MA, Shapiro SE, Lee JE, Evans DB, Perrier ND. Surgical management of thyroid carcinoma. J Natl Comprehensive Cancer Network 2005; 3:458–466.

    Google Scholar 

  52. Loh K-C, Greenspan FS, Gee L, et al. Pathological tumor-nodemetastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82:3553–3562.

    Article  PubMed  CAS  Google Scholar 

  53. Esnaola NF, Cantor SB, Sherman SI, et al. Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis. Surgery 2001; 130:921–930.

    Article  PubMed  CAS  Google Scholar 

  54. Dackiw APB, Zeiger M. Extent of surgery for differentiated thyroid cancer. Surg Clin N Am 2004; 84:817–832.

    Article  PubMed  Google Scholar 

  55. Simpson WJ, McKinney SE, Carruthers JS, et al. Papillary and follicular thyroid cancer: prognostic factors in 1578 patients. Am J Med 1987; 83:479–488.

    Article  PubMed  CAS  Google Scholar 

  56. Mazzaferri EL. Thyroid remnant 131-I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7:265–271.

    PubMed  CAS  Google Scholar 

  57. Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977; 56:171–196.

    Article  PubMed  CAS  Google Scholar 

  58. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511–518.

    Article  PubMed  CAS  Google Scholar 

  59. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a population based study of 15698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997; 79:564–573.

    Article  PubMed  CAS  Google Scholar 

  60. Samaan NA, Schultz PN, Hickey RC, et al. Well differentiated thyroid carcinoma and the results of various modalities of treatment: a retrospective review of 1599 cases. J Clin Endocrinol Metab 1992; 75:714–720.

    Article  PubMed  CAS  Google Scholar 

  61. American Joint Committee on Cancer. The Thyroid Gland. In AJCC Cancer Staging Manual, 6th Edition, Springer, New York, NY, 2002; pp. 77–87.

    Google Scholar 

  62. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocr Metab Clin North Am 1995; 24:803–840.

    CAS  Google Scholar 

  63. Heufelder AE, Gorman CA. Radioiodine therapy in the treatment of differentiated thyroid cancer: guidelines and considerations. Endocrinologist 1991; 1:273–280.

    Google Scholar 

  64. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89:1666–1673.

    Article  PubMed  CAS  Google Scholar 

  65. Sawka AM, Thephamongkhol K, Brouwers M, et al. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668–3676.

    Article  PubMed  CAS  Google Scholar 

  66. Mazzaferri E. Editorial: A randomized trial of remnant ablation-in search of an impossible dream? J Clin Endocrinol Metab 2004; 89:3662–3664.

    Article  PubMed  CAS  Google Scholar 

  67. Haugen BR. Editorial: patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab 2004; 89:3665–3667.

    Article  PubMed  CAS  Google Scholar 

  68. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer 2005; 12:49–64.

    Article  PubMed  CAS  Google Scholar 

  69. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88:4110–4115.

    Article  PubMed  CAS  Google Scholar 

  70. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131-I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063–4068.

    Article  PubMed  CAS  Google Scholar 

  71. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001; 11:865–869.

    Article  PubMed  CAS  Google Scholar 

  72. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002; 43:1482–1488.

    PubMed  CAS  Google Scholar 

  73. Spencer CA. New insights for using serum thyroglobulin (Tg) measurement for managing patients with differentiated thyroid carcinomas. Thyroid International 2003; 4:1–14.

    Google Scholar 

  74. Whitley RJ, Ain KB. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clinics Lab Med 2004; 24:29–47.

    Article  Google Scholar 

  75. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004; 45:988–994.

    PubMed  CAS  Google Scholar 

  76. Ligabue A, Possgioli MC, Zacchini A. Interference of specific autoantibodies in the assessment of serum thyroglobulin. J Nucl Biol Med 1993; 37:273–279.

    PubMed  CAS  Google Scholar 

  77. Ringel MD, Balducci-Silano PL, Anderson JS, et al. Quantitative reverse transcription polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:4037–4042.

    Article  PubMed  CAS  Google Scholar 

  78. Chinnappa P, Taguba L, Arciaga R, et al. Detection of thyrotropinreceptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 2004; 89:3704–3709.

    Article  CAS  Google Scholar 

  79. Li D, Butt A, Clarke S, Swaminathana R. Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects. Ann NY Acad Sci 2004; 1022:147–151.

    Article  PubMed  CAS  Google Scholar 

  80. Spencer CA. Editorial: Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004; 89:3702–3704.

    Article  PubMed  CAS  Google Scholar 

  81. Elisei R, Vivaldi A, Agate L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab 2004; 89:33–39.

    Article  PubMed  CAS  Google Scholar 

  82. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433–1441.

    Article  PubMed  CAS  Google Scholar 

  83. Wartofsky L. Editorial: Using baseline and recombinant human TSHstimulated Tg measurements to manage thyroid cancer without diagnostic 131-I scanning. J Clin Endocrinol Metab 2002; 87:1486–1489.

    Article  PubMed  CAS  Google Scholar 

  84. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490–1498.

    Google Scholar 

  85. Robbins RJ, Chon JT, Fleisher M, et al. Is te serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87:3242–3247.

    Article  PubMed  CAS  Google Scholar 

  86. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:3668–3673.

    Article  PubMed  CAS  Google Scholar 

  87. Antonelli A, Miccoli P, Fallahi P, et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 2003; 13:479–484.

    Article  PubMed  Google Scholar 

  88. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: A review. Thyroid 2002; 12:683–702.

    Article  PubMed  Google Scholar 

  89. Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002; 12:121–134.

    Article  PubMed  Google Scholar 

  90. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44:451–456.

    PubMed  CAS  Google Scholar 

  91. Sgouros G, Kolbert KS, Sheikh A, et al. Patient specific dosimetry for 131-I thyroid cancer therapy using 124-I PET and 3-dimensionalinternal dosimetry (3D-ID) software. J Nucl Med 2004; 45:1366–1372.

    PubMed  CAS  Google Scholar 

  92. de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131-I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 2004; 45:1549–1554.

    PubMed  Google Scholar 

  93. Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med 2005; 46:1079–1088.

    PubMed  Google Scholar 

  94. Ma C, Xie J, Kuang A. Is empiric 131-I therapy justified for patients with positive thyroglobulin and negative 131-K whole-body scanning results? J Nucl Med 2005; 46:1164–1170.

    PubMed  Google Scholar 

  95. Park J-W, Clark OH. Redifferentiation therapy for thyroid cancer. Surg Clin N Am 2004; 84:921–943.

    Article  PubMed  Google Scholar 

  96. Braga-Basaria M, Ringel MD. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 2003; 88:1947–1960.

    Article  PubMed  CAS  Google Scholar 

  97. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current status and future prospects. Thyroid 2004; 14:424–434.

    Article  PubMed  CAS  Google Scholar 

  98. Tubiana M, Haddad E, Schlumberger M, et al. External radiotherapy in thyroid cancers. Cancer 1985; 55:2062–2071.

    Article  PubMed  CAS  Google Scholar 

  99. Simpson WJ, Carruthers JS. The role of external radiation in the management of papillary and follicular thyroid cancer. Am J Surg 1978; 136:457.

    Article  PubMed  CAS  Google Scholar 

  100. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987; 10:303.

    PubMed  CAS  Google Scholar 

  101. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155–2160.

    Article  PubMed  CAS  Google Scholar 

  102. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with a combination of doxorubicin and radiation therapy. Cancer 1987; 60:2372–2375.

    Article  PubMed  CAS  Google Scholar 

  103. Mazzaferri EL. An overview of the management of papillary and follicular thyroid cancer. Thyroid 1999; 9:421–427.

    PubMed  CAS  Google Scholar 

  104. Ladenson PW. Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid 1999; 9:429–433.

    Article  PubMed  CAS  Google Scholar 

  105. Robbins RJ, Robbins AK. Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003; 88:1933–1938.

    Article  PubMed  CAS  Google Scholar 

  106. Burguera B, Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrin Metab Clin N Am 2000; 29:187–203.

    Article  CAS  Google Scholar 

  107. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992; 112:1139–1147.

    PubMed  CAS  Google Scholar 

  108. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115:237–243.

    Article  PubMed  Google Scholar 

  109. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130:941–946.

    Article  PubMed  CAS  Google Scholar 

  110. Kang HW, Kim S-K, Kang H-S, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003; 88:4100–4104.

    Article  PubMed  CAS  Google Scholar 

  111. Pellegriti G, Scollo C, Lumera G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: Study of 299 cases. J Clin Endocrinol Metab 2004; 89:3713–3720.

    Article  PubMed  CAS  Google Scholar 

  112. Pearce EN, Braverman LE. Editorial: Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab 2004; 89:3710–3712.

    Article  PubMed  CAS  Google Scholar 

  113. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13:381–387.

    Article  PubMed  Google Scholar 

  114. Silver RJ, Parangi S. Management of thyroid incidentalomas. Surg Clin N Am 2004; 84:907–919.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Washington Hospital Center, Washington, DC

    Leonard Wartofsky MD (Chairman, Professor of Medicine)

  2. Anatomy, Physiology and Genetics, Uniformed Services University of Health Sciences, Bethesda, MD

    Leonard Wartofsky MD (Chairman, Professor of Medicine)

  3. Georgetown University School of Medicine, Washington, DC

    Leonard Wartofsky MD (Chairman, Professor of Medicine)

Authors
  1. Leonard Wartofsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Washington Hospital Center, Washington, DC

    Leonard Wartofsky MD, MPH, MACP  & Douglas Van Nostrand MD, FACP, FACNP  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Wartofsky, L. (2006). Papillary Carcinoma. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-995-0_23

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-462-3

  • Online ISBN: 978-1-59259-995-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation